Compare IONQ Inc (IONQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs State Street SPDR S&P Biotech ETF — how do they compare? IONQ Inc trades at $39.89 (market cap $15.98B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: IONQ Inc is the larger of the two by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IONQ | XBI | |
|---|---|---|
Market Cap | $15.98B | $10.11B |
Volume | 22,848,240 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $82.09 | $169.55 |
52-Week Low | $26.59 | $104.99 |
Typical Hold Time | 33 Days | 38 Days |
Enterprise Value | $13.92B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.45, down 4.57% today, showing bearish technical signals with mixed fundamental performance. The company reported strong revenue growth ($130M in 2025, projected $246M in 2026) but significant losses (-$510M net income in 2025). Recent earnings show a pattern of beats and misses, with Q2 2026 missing expectations. Technical indicators show bearish momentum despite some oversold conditions, with key support at $36 and resistance at $41.
Outlook remains speculative with high growth potential but substantial execution risks. Analyst consensus is split with a $62.75 price target suggesting 59% upside, though profitability challenges and cash burn (-$283M operating cash flow in 2025) present significant hurdles. The quantum computing market opportunity is substantial, but IONQ must demonstrate path to profitability to justify current valuations.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
